Amplia Therapeutics Limited, a pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline includes AMP945, an inhibitor of FAK that has completed Phase I clinical trial for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases; and AMP886 for treating acute myeloid leukemia and various solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
0.07 | |
0.064 | |
- | |
0.07 | |
0.064 | |
0.025-0.08 | |
12 038 K | |
274 M | |
4 453 K | |
-0.004 | |
0.646 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: